SSY Group (02005.HK): Cimetidine Injection and Acetylcysteine Solution for Inhalation Obtain Manufacturing Registration Approvals

NewTimeSpace News: SSY Group Limited (02005.HK) issued a voluntary announcement on July 30, 2026, disclosing that the Group has obtained a drug manufacturing registration approval from the NMPA for Cimetidine Injection (2ml:0.2g), which is classified as a Category 3 chemical drug and deemed to have passed the consistency evaluation. Cimetidine Injection is primarily indicated for the treatment of gastrointestinal ulcers.

Concurrently, the Group has obtained a drug manufacturing registration approval from the NMPA for Acetylcysteine Solution for Inhalation (3ml:0.3g), classified as a Category 4 chemical drug and deemed to have passed the consistency evaluation. This product is primarily indicated for the treatment of respiratory diseases accompanied by excessive thick mucus secretions, such as acute bronchitis, chronic bronchitis and its exacerbations, emphysema, mucoviscidosis, and bronchiectasis. This product further enriches the Group's expectorant nebulizer portfolio and expands the Group's nebulized inhalation treatment options for respiratory diseases.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.